Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 17,43 € (+0,35 %). Medianen er 17,43 € (+0,35 %).
| Køb |
4 |
| Behold |
10 |
| Sælg |
0 |
Nyheder Til nyhedsfeedet
Jim Cramer’s trust buys Kimberly-Clark ahead of Kenvue deal completion
Jim Cramer’s Charitable Trust bought 50 shares of Kimberly-Clark at about $95.80, bringing its holding to 515 shares and raising the position to roughly 1.24% of the portfolio. The purchase is part of a broader move to deploy a large cash balance into beaten-down non-tech names, with the trust citing the near-term catalyst of the nearly $50 billion Kenvue acquisition expected before year-end. The trust highlights Kimberly-Clark’s 5.3% yield, a roughly 13x forward earnings valuation, and confidence in CEO Mike Hsu to extract more value from Kenvue’s brands via club, e-commerce and international expansion. » Mere på cnbc.com
Kimberly-Clark offers asset sales to win EU approval for $40bn Kenvue deal
Kimberly-Clark is preparing to divest Kenvue assets to address EU antitrust concerns and aims to secure European Commission approval by the September 29 deadline to avoid a lengthier investigation. The company has already faced similar demands in Australia, where conditional approval required selling Carefree and Stayfree. The acquisition would create a consumer-health and personal-care group with about $32 billion in revenue and $7 billion of adjusted EBITDA; Kimberly-Clark cites roughly $1.9 billion in annual cost synergies and $500 million in revenue synergies but expects to invest $2.5 billion to realize cost savings. The scale of any EU divestitures will determine how much of the deal’s expected economic benefits are preserved, while broader remedies or a prolonged review could reduce acquired earnings and delay synergy realization. » Mere på finance.yahoo.com
Kenvue pays quarterly dividend of $0.21 on Oct. 2
Kenvue's board of directors approved a quarterly dividend of $0.21 per common share. The payment will be made on October 2, 2026, to shareholders of record at the close of business on September 21, 2026. » Mere på de.investing.com
Historisk udbytte Udbytte
Alle nøgletal for udbytte Alle nøgletalVirksomhedstal
| (EUR) | juni 2026 | YoY |
|---|---|---|
| Omsætning | 3,47 mia. | 6,10 % |
| Bruttofortjeneste | 2,02 mia. | 4,81 % |
| Nettoresultat | 400,49 mio. | 11,82 % |
| EBITDA | 731,59 mio. | 2,50 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 33,59 mia. € |
Antal aktier | 1,92 mia. |
Højeste/laveste i 52 uger | 17,99 € - 12,53 € |
Udbytteafkast | 4,14 % |
Udbytte TTM | 0,72 € |
Beta | 0,45 |
P/E (PE Ratio) | 22,49 |
PEG (PEG Ratio) | 1,28 |
K/I (PB Ratio) | 3,56 |
P/S (PS Ratio) | 2,44 |
Virksomhedsprofil
Kenvue Inc. driver som et forbrugersundhedsselskab på verdensplan. Selskabet opererer gennem tre segmenter: Self Care, Skin Health and Beauty og Essential Health. Segmentet Self Care tilbyder produkter mod hoste, forkølelse og allergi, smertebehandling, mave-tarm-sundhed, rygestop og andre produkter under mærkerne Tylenol, Nicorette og Zyrtec. Segmentet Skin Health and Beauty leverer ansigts- og kropspleje, hårpleje samt solcreme og andre plejeprodukter under mærkerne Neutrogena, Aveeno og OGX. Segmentet Essential Health tilbyder mund- og babypleje, kvindesundhed og sårpleje under mærkerne Listerine, Johnson's, Band-Aid og Stayfree. Selskabet blev stiftet i 2022 og har hovedkontor i Skillman, New Jersey. Kenvue Inc. er et datterselskab af Johnson & Johnson.
| Navn | Kenvue |
| CEO | Kirk L. Perry |
| Hjemsted | Summit,
nj USA |
| Websted | |
| Sektor | Dagligvarer |
| Branche | Dagligvarer: distribution og detailhandel |
| Børsnotering | 04.05.2023 |
| Medarbejdere | 21.890 |
Tickersymboler
| Børs | Symbol |
|---|---|
NYSE | KVUE |
Frankfurt | J4D.F |
Düsseldorf | J4D.DU |
Hamburg | J4D.HM |
München | J4D.MU |